Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells

Sepantronium bromide (YM155), originally developed against the anti-apoptotic protein survivin, performed exceptionally well in pre-clinical and phase I clinical trials. However, in phase II trials of several cancer types including breast cancer it performed poorly. Additionally, no definitive corre...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Wani, Tasaduq H., Surendran, Sreeraj, Mishra, Vishnu S., Chaturvedi, Jaya, Chowdhury, Goutam, Chakrabarty, Anindita
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2018
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6173358/
https://ncbi.nlm.nih.gov/pubmed/30323901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26096
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы